# Outcomes of patients with anal cancer treated with definitive chemoradiation: A single centre experience

## TL;DR

This study examines the effectiveness of chemoradiation for treating non-metastatic anal cancer in a single center, finding high response rates and moderate survival outcomes.

## Contribution

The study provides the first review of anal cancer incidence and treatment outcomes in Pakistan.

## Key findings

- More than 80% of patients had complete radiological responses after chemoradiation.
- The 2-year disease-free survival rate was over two-thirds among surviving participants.

## Abstract

Anal cancers are uncommon neoplasms that make up to <1% of all tumours globally. Concurrent chemoradiation remains the standard of care treatment for patients who present with non-metastatic anal squamous cell carcinomas (ASCCs).

We aimed to evaluate the response rate and 2-year survival outcome of the definitive chemoradiation approach in patients with non-metastatic ASCCs of our population. We conducted a cross-sectional review of these patient populations who were treated and then followed after completion of treatment at our institute during the last 10 years.

A total of 17 patients were enrolled after fulfillment of the eligibility criteria. The responses were documented in 16 patients through magnetic resonance imaging or computed tomography of the pelvis, done at 3 months of treatment completion. More than 80% of the patients had complete radiological responses. Among the surviving participants, the 2-year disease-free survival rate was found to be more than two-thirds. Approximately 20% of the study participants had disease recurrence during the subsequent clinic visits following treatment completion.

This review emphasises the impact of definitive chemo-radiation in achieving radiological and clinical responses in patients with non-metastatic ASCCs. Moreover, to our knowledge, this is the first review to highlight anal cancer’s incidence and characteristics in Pakistan.